A DAD died after taking a weight loss jab for just a few weeks. Tim Ramsay, from South Australia, wanted to shed some pounds so he could confidently walk his daughter down the aisle. The ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Novo Nordisk latest news, photos, videos, breaking news, special reports, blogs, and updates from Business Insider India ...

Voters will elect a host of new faces to represent them in North Carolina’s executive branch this Election Day. Follow along ...

Dow Jones Industrial Average futures soared more than 480 points, or 1.2%. Bitcoin, which is seen as benefiting from a Trump ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Monday was very much a good news/bad news kind of day. The company reported quite encouraging clinical results from a version ...

It can be harder to lose weight after a certain age, which is why GLP-1 medications can be incredibly useful. That's where ...

Always speak with your doctor before starting any new supplement or exercise ... keeping you on track even after you’re done ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...